Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin
(Cat. No. 2251) and shows antitumor activity in cell lines with acquired cisplatin resistance.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy et al.
Cellular and molecular pharmacology of oxaliplatin.
Raymond et al.
Mol.Cancer Ther., 2002;1:227
Oxaliplatin: a review of evolving concepts.
Mani et al.
Cancer Invest., 2002;20:246
The citations listed below are publications that use Tocris products. Selected citations for Oxaliplatin include:
Showing Results 1 - 6 of 6